Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.44 |
| ▸ | LIPE | Q05469 | 1/20 | 0.44 |
| ▸ | GPR6 | P46095 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CCR6 | P51684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2810661 | 1.00 | EPHX2 (0.44) | EPHX2LIPEGPR6MEN1KMT2A | |
| SCHEMBL8118131 | 1.00 | EPHX2 (0.44) | EPHX2LIPEGPR6MEN1KMT2A | |
| SCHEMBL2811084 | 0.89 | MEN1 (0.44) | EPHX2LIPEGPR6MEN1KMT2A | |
| SCHEMBL2811082 | 0.89 | MEN1 (0.44) | EPHX2LIPEGPR6MEN1KMT2A | |
| SCHEMBL2811085 | 0.89 | MEN1 (0.44) | EPHX2LIPEGPR6MEN1KMT2A | |
| SCHEMBL13167769 | 0.88 | LMNA (0.41) | EPHX2SFRP1AKR1C3LMNACCR6 | |
| SCHEMBL13130723 | 0.85 | EPHX2 (0.44) | EPHX2LIPEMEN1KMT2AEPHX1 | |
| SCHEMBL3637085 | 0.83 | MGLL (0.34) | EPHX2 | |
| SCHEMBL1677066 | 0.81 | GPR6 (0.48) | EPHX2LIPEGPR6MEN1KMT2A | |
| SCHEMBL2808569 | 0.80 | MEN1 (0.45) | EPHX2LIPEGPR6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563732-B2 | Oxyimino compounds and the use thereof | SHIONOGI & CO., LTD. (JP) | 2013-10-22 | — | — | US | disclosed |
| EP-2164325-B1 | OXYIMINO COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO (JP) | 2013-04-24 | — | — | EP | disclosed |
| US-20100240703-A1 | OXYIMINO COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2010-09-23 | — | — | US | disclosed |
| EP-2164325-A1 | OXYIMINO COMPOUNDS AND THE USE THEREOF | Shionogi&Co., Ltd. (JP) | 2010-03-24 | — | — | EP | disclosed |
| WO-2008150470-A1 | OXYIMINO COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240703-A1 | OXYIMINO COMPOUNDS AND THE USE THEREOF | CACNA1A, CACNA1S, OPRM1 | EPHX2 653/4885LIPE 4133/4885GPR6 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.